Experimental t cell therapy targets Hard-to-Treat KRAS cancers
NCT ID NCT06546150
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new treatment called RE002 T cells for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The study will enroll 30 adults who have run out of standard options. Participants first receive chemotherapy to prepare their immune system, then get the RE002 T cell infusion. The main goal is to see if the tumors shrink and to check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RE002 T cells (a type of immune cell therapy)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have a specific KRAS mutation.
What could go wrong
This is a very early Phase 1 trial with only 30 participants, so it is not yet known if the treatment works or is safe. There are risks from the chemotherapy given beforehand and possible side effects from the T cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS G12D are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, 450008, China
Contact